By Colin Kellaher
Shares of Candel Therapeutics took flight in premarket trading Wednesday after the clinical-stage biopharmaceutical company said a late-stage study of its CAN-2409 product candidate met its key goal in prostate cancer.
Candel said the multicenter phase 3 study evaluating CAN-2409 viral immunotherapy achieved its primary endpoint, showing statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate- to high-risk, localized prostate cancer.
The Needham, Mass., company said it plans to initiate talks with the Food and Drug Administration on the regulatory pathway for CAN-2409 in intermediate- to high-risk localized prostate cancer.
Candel shares, which closed Tuesday at $4.61, were recently up 133% to $10.75 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 11, 2024 07:51 ET (12:51 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.